225Ac-PSMA-617 放射性配体治疗后影像学在使用 3 个光峰的转移性去势抵抗性前列腺癌患者中的应用。
225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
机构信息
Medical Oncology, Regional Cancer Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
From the Department of Nuclear Medicine, Nehru Hospital.
出版信息
Clin Nucl Med. 2020 Jun;45(6):437-438. doi: 10.1097/RLU.0000000000003031.
PSMA-based radioligand therapies have shown the beneficial effect in metastatic castrate-resistant prostate cancer (mCRPC) patients when they become refectory to the established treatments with associated potential toxicities and high mortality rate. Ac-PSMA therapy is known to be remarkably effective in substantially pretreated mCRPC patients. However, posttherapy imaging is usually not performed as alpha emitters are really difficult to image. We presents a patient of mCRPC treated with Ac-PSMA-617, and his posttherapy whole-body scans acquired by using 3 different photopeaks (78, 218, and 440 keV) fairly demonstrated the tracer's distribution and the efficacy of targeted alpha therapy.
基于 PSMA 的放射性配体疗法在转移性去势抵抗性前列腺癌（mCRPC）患者对既定治疗产生抗药性时显示出有益的效果，这些治疗方法伴随着潜在的毒性和高死亡率。Ac-PSMA 疗法在经过大量预处理的 mCRPC 患者中被证实非常有效。然而，由于α发射体确实很难成像，因此通常不会进行治疗后成像。我们介绍了一位接受 Ac-PSMA-617 治疗的 mCRPC 患者，他的治疗后全身扫描使用了 3 种不同的光峰（78keV、218keV 和 440keV），这些光峰相当好地显示了示踪剂的分布和靶向α治疗的疗效。
Zotero 插件